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Objectives: Although several studies reported patients with chronic disease were 
found to have lower medication adherence and higher discontinuation rates as 
disease duration increased, it is still not evident in glaucoma patients. With this 
perspective, this study was designed to assess the association of disease dura-
tion with medication adherence and discontinuation in glaucoma patients in 
Korea. MethOds: It was a cross-sectional, multi-centered and observational study 
where glaucoma outpatients with less than two years of drug use were recruited at 
15 eye clinics from March to November 2013. All patients completed a self-admin-
istered questionnaire asking about their daily use of glaucoma medications to esti-
mate adherence and discontinuation. Medication adherence and discontinuation 
were defined as patients administering the drug for ≥ 80% of prescribed days and if 
patients stopped taking medication for 7 consecutive days respectively. Results: 
A total of 1,050 glaucoma patients were enrolled in the study. Of the total, 14.4% 
showed to be non-adherent to their glaucoma therapy and 7.5% had the experi-
ence of medication discontinuation. All patients were categorized into 3 groups 
according to disease duration: group A ≤ 1 year (n= 600,57.1%), B > 1 year and ≤ 2 
years (n= 415,39.5%), and C > 2 years (n= 35,3. 3%). The patients of group A with 
the disease duration ≤ 1 year were likely to be non-adherent to glaucoma therapy 
compared to those with longer disease duration. (A: 84.9% vs. B: 86% vs. C: 100%, 
p= . 045) Highest discontinuation rate was found in group B with the disease duration 
bewteen 1 and 2 years. (A: 6.7% vs. B: 8.9% vs. C: 5.7%, P= . 380) cOnclusiOns: The 
study results highlight more attention should be paid to the patients who newly 
started glaucoma therapy because in the patients with less than 2 years of disease 
duration the adherence was low and the discontinuation rate was high.
PSS39
HealtH State UtilitieS for PreSSUre UlcerS – a comPariSon of 
condition-SPecific and Generic meaSUreS and time-trade-off (tto)
Meads D.M.1, Czoski-Murray C.1, Rutherford C.2, Dealey C.3, McGinnis E.4, Stubbs N.5, Wilson 
L.1, Nixon J.1, Hulme C.T.1, McCabe C.6
1University of Leeds, Leeds, UK, 2University of Sydney, Sydney, Australia, 3Birmingham Hospitals 
NHS Trust and University of Birmingham, Birmingham, UK, 4Leeds Teaching Hospitals NHS Trust, 
Leeds, UK, 5Leeds Community Healthcare NHS Trust, Leeds, UK, 6University of Alberta, Edmonton, 
AB, Canada
Objectives: To compare a newly developed condition-specific utility index (CSUI), 
the Pressure Ulcer Quality of Life Utility Index (PUQoL-UI) with generic and directly 
elicited TTO values. MethOds: The PUQoL-UI was completed by a group of patients 
(n= 100) in England with pressure ulcers (PUs) along with the EQ-5D and own health 
TTO. The discriminatory power of the utility measures was assessed across PU 
grade and health and PU severity ratings. Multivariate regression was conducted 
to explore determinants of utility values. Results: The mean sample age was 77.2 
years (range 22.7-101.7), 49% were female and 50% wheelchair users. Mean (SDs) 
utility for superficial PUs (grades 1-2) were 0.72 (0.17), 0.70 (0.35) and 0.24 (0.16) and 
for severe PUs (grades 3-4) 0.67 (0.17), 0.65 (0.35) and 0.15 (0.38) for the PUQoL-UI, TTO 
and EQ-5D, respectively. Mean (SDs) utility by self-reported PU severity was: [Mild] 
0.78 (0.16), 0.66 (0.35), 0.29 (0.36); [Moderate] 0.72 (0.17), 0.63 (0.38), 0.25 (0.34); [Severe] 
0.58 (0.17), 0.70 (0.33), 0.04 (0.40) for the PUQoL-UI, TTO and EQ-5D, respectively. 
Regression analyses indicated both EQ-5D and PUQoL-UI values were explained by 
perceived severity and general health ratings but not demographics or PU grade. 
Duration and body part affected were additional significant explanatory factors of 
the EQ-5D while wheelchair use approached significance. cOnclusiOns: Values 
were much lower for the EQ-5D than the other assessments which may be partly 
explained by the range in EQ-5D and partly due to background mobility issues being 
captured. The PUQoL-UI appears to have good discriminatory power and is recom-
mended for use in trials of PU interventions. The utilities presented here will be use-
ful for decision-analytic models that incorporate PU impact. Probabilistic sensitivity 
analyses including the PUQoL-UI will likely generate lower levels of uncertainty than 
the EQ-5D due to the smaller SDs for health states.
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Objectives: To obtain utility estimates suitable for use in economic models for 
chronic spontaneous (idiopathic) urticaria (CSU). MethOds: Patient-level data from 
three randomised clinical trials: ASTERIA I, ASTERIA II, and GLACIAL were analysed. 
Health states were derived from Urticaria Activity Score (UAS7), a patient-completed 
diary of signs and symptoms which calculates an average daily score over 7 days. 
Higher score means more severe symptoms. UAS7 scores for the health states were: 
Urticaria-free: 0; Well-controlled urticaria: 1-6; Mild urticaria: 7-15; Moderate urti-
caria: 16-27; Severe urticaria: 28-42. Mean EQ-5D utilities were calculated for each 
health state. Individual trial analyses showed inconsistent utilities across the UAS7 
health states due to small subsample sizes. A mixed model was used to predict 
EQ-5D according to UAS7 health states in a pooled dataset containing all treatment 
arms and time-points from the three trials. The predictor variable was UAS7 health 
state and the dependent variable was EQ-5D utility. Fixed/random effects for trial 
and patient were included and the following covariates: UAS7 health state at base-
line (Moderate or Severe), presence of angioedema at baseline and during follow-up, 
duration of CSU, number of previous CSU medications, and gender of the patient. 
A parsimonious model was selected using the approach of backwards elimination; 
UAS7 health state was forced into the model. The validity of pooling trials was con-
sidered through visual comparisons and interaction terms. Results: There was a 
consistent improvement in EQ-5D utilities as severity of urticaria improved. Mean 
utilities at Week 12 ranged from 0.712 in patients with severe urticaria to 0.897 in 
patients who were urticaria-free. Sensitivity analysis confirmed the robustness of 
results. cOnclusiOns: The results suggest that EQ-5D utility score increased with 
decreasing severity of urticaria. EQ-5D utility scores allow the comparison of HRQoL 
across diseases by calculating QALYs in economic models.
states were determined on the basis of published literature. For next generation 
AVDs, which are currently tested in clinical trials, various possible effect and 
pricing scenarios have been simulated. Results: Applying the base case settings 
resulted in incremental costs of € 107,925, in 2.03 incremental quality-adjusted 
life years (QALYs) and in a cost-effectiveness ratio of € 53,165 per QALY gained. 
Probabilistic and deterministic sensitivity analyses as well as scenario analyses 
for the effect size and the AVD costs were performed in order to investigate the 
robustness of results. In these analyses a strong variation of the cost-effectiveness 
results was obtained ranging from € 23,512 (best case) to € 176,958 (worst case) 
per QALY gained. cOnclusiOns: The innovative nature, the high unmet medi-
cal need and the expected unprecedented efficacy of next generation AVDs will 
highly likely lead to the case that even relatively high incremental cost effective-
ness ratios, that have been obtained when simulating various effect and pric-
ing scenarios, will be regarded as acceptable from a German health care payer 
perspective.
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Objectives: Intraoperative threshold measurement is a part of the cochlear 
implantation procedure and in the current setting conducted by the clinicians 
with a standard set-up. The newly released CR220 Intraoperative Remote Assistant 
is a handheld device and can also be used by someone already in the operating 
theatre (OT). The aim of this study was to compare measurement time with the 
new CR220 and standard set-up and to investigate from the clinic’s perspective any 
cost-savings created as a result of time-savings with the new device. MethOds: 
Stages of the measurement process are identified and the time is measured 
for each stage during 113 patients’ implantation procedure. A literature review 
was conducted to identify the reimbursement level of this process in order to 
translate any time-savings to cost savings. Results: When the clinician trav-
els to the OT, the mean time spent per procedure with CR220 is 8.4% less than 
the computer set-up (163.7 minutes vs 149.9 minutes). If the measurement is 
conducted by someone already in the OR, the measurement time is reduced by 
95.5% with the CR220 (163.7 minutes vs 7.3 min). Literature review revealed that 
the fee for measurement as $18.99-22.57 per 15 minutes in the US setting and 
in most of the other settings this procedure is not reimbursed separately but 
covered under cochlear implantation. cOnclusiOns: The analysis showed that 
considerable time is spent for the clinician to travel to OT and waiting in the OT. 
This “unproductive” time is not only wasteful, but also means the clinician is not 
available in the clinic seeing patients where their expert skills are of most value. 
Moreover the clinic is either underpaid or is not paid at all for this expertise and 
time demanding process. The new CR220 gives clinics the opportunity to allocate 
their limited resources efficiently.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
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Objectives: There are few studies combining dose regimen in routine clinical 
practice, drug survival rates and costs of biological agents for the treatment of 
naïve patients with moderate-to-severe psoriasis in the clinical practice. To assess 
the dose regimen in routine clinical practice, drug survival rate (persistence rate) 
and efficiency (cost per persistence) for etanercept (ETN), adalimumab (ADA) and 
ustekinumab (UST) in a real practice clinical setting. MethOds: A retrospective 
study on psoriasis patients aged ≥ 18 years, naïve to a biological agent and a mini-
mum of 6 months of treatment was performed in 5 public health system hospitals 
in the Balearic Islands (Spain) for the period from January 1st 2010 to December 31st 
2013. The recorded variables were: sex, weight, age, indication (psoriasis or psoriatic 
arthritis), discontinuation reason and pharmacy dispensation records. Costs were 
based on the average wholesale price, estimating annual cost according to the first 
treatment received. Persistence rates were reckoned taking into account the cur-
rent total days of therapy comparing posology with pharmacy supplied dose, and 
were estimated using the method of Kaplan-Meier. Results: During the study 
period a cohort of 112 psoriatic patients (57% men) were evaluated: 37 patients 
with ADA (81 kg, 51 years, 27; mean weight, mean age, and prevalence of psoriatic 
arthritis respectively), 34 with ETN (82 kg, 52 years, 25%) and 41 with UST (76 kg, 43 
years, 19%). The persistence rate at 2 years was, 48%, 62% and 81% and the cost per 
persistence at 2 years was 52.961 € , 40.160 € , and 30.657 € (for ADA, ETN and UST 
respectively). cOnclusiOns: UST showed better overall drug survival compared 
to ETN and ADA. UST has been the most efficient alternative for the treatment of 
naïve patients and has shown the least budget-impact per persistent-patient at 2 
years analysis.
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